GLPwatch
Trials (2101)
Page 18 of 36.
- Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
- A Study of XW003 Injection in Chinese Adolescents With Obesity
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Safety and Efficacy of Exenatide as Monotherapy
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
- Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
- A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
- Specific Clinical Experience Investigation for Long-term Use of Bydureon.
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
- GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations
- Anti-diabetic Drugs and Fatty Liver Management
- In-patient Study in Patients With Type 2 Diabetes Mellitus
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- A Study of CS060380 Tablets in Patients With MASH and Obesity
- Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
- Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
- GLP1R Polymorphisms and Response to GLP1
- Genetics of the Acute Response to Oral Semaglutide
- Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
- Protein Supplementation Intervention on Body Weight
- Liraglutide in Type 1 Diabetes
- Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
- A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
- The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
- Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
- Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
- LIraglutide and Beta-cell RepAir (LIBRA) Study
- Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
- A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
- Study of the Effects of Intravenous Exenatide on Cardiac Repolarization
- A Comparison of Exenatide and Insulin Glargine
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
- Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
- Separate and Combined Extrapancreatic Effects of GIP and GLP-1
- Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
- Semaglutide in Treatment of Obesity
- Lecanemab for Early Onset Familial Alzheimer's Disease
- Safety and Efficacy of Liraglutide in Parkinson's Disease
- Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
- Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
- Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
- Closed Loop System With Pramlintide Versus Exenatide
- Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)
- A Study of LY3493269 in Participants With Type 2 Diabetes
- Study of RO6807952 in Patients With Diabetes Mellitus Type 2
- Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus
- A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
- A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks
- A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
- A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
- Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake
- A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
- Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.
- Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
- Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers